Cilnidipine is a fourth-generation calcium channel blocker that may offer unique benefits compared to other L-type CCBs in the management of hypertension.
May support pathophysiology-guided CCB selection in hypertension; leaves open randomized trials to confirm benefits over L-type agents.
Several classes of antihypertensive agents have been in clinical use, including diuretics, α-blockers, β-blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II type 1 receptor blockers (ARB), and organic calcium channel blockers (CCBs). All these drugs are being currently used in the treatment of Hypertension & various disease conditions of the heart either alone or in combination. Cilnidipine is a new antihypertensive drug distinguished from other L-type Ca(2+) channel blockers or even other antihypertensives, which will be useful for selection of antihypertensive drugs according to the pathophysiological condition of a patient.
No takes yet. Share an insight, caveat, or question.
Chandra et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: